Xenta secures Series A funding, aiming to pioneer a new era in POCT with dry chemiluminescence

Xenta Biomedical Science co, Ltd ("Xenta") announced the completion of a Series A financing round totaling tens of millions of RMB. This round was led by Huayi Capital (华屹资本), with continued participation from existing shareholders Kents Capital and Guangzhou Weiyin (广州未垠). Since its establishment just over three years ago, the company has successfully raised nearly 50 million yuan through previous angel and pre-A rounds, demonstrating strong fundraising capabilities.

The proceeds will be used to accelerate the China registration and certification process for its innovative products, support the global market expansion and production of its CE/FDA-certified products, and increase investment in new product development to further enrich its testing menu.

Founded in 2022, Xenta has established a diversified technology portfolio centered on its core "Light-Activated Chemiluminescence" platform. This system encompasses a dry light-activated chemiluminescence POCT platform, a chip-based ultra-multiplex molecular POCT platform, and an immunochromatographic POCT platform. The company's product pipeline covers diverse testing scenarios including cardiovascular diseases, inflammation, hormones, oncology, thyroid function, diabetes, prenatal and childcare, and infectious pathogens, addressing both primary rapid testing needs and high-end precision diagnostics markets.

Currently, Xenta has established R&D centers in Guangzhou and Xiamen, with holding subsidiaries in Foshan and the United States. The company obtained ISO 13485 international quality management system certification in 2022 and was designated as a National High-Tech Enterprise in China in 2024.

To date, Xenta has secured nearly 100 product certifications from multiple regulatory authorities including CE, FDA, Indonesia, and China's NMPA. The company recently obtained IVDR certification for its light-activated device X-LAB MINI and is advancing NMPA registration for nine products including cardiac markers, inflammation, diabetes, and light-activated devices, with anticipated commercial launch in China by spring 2026.